Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Project

The study of the therapeutic potential of PPARa-ERRa ligand combinations in non-alcoholic fatty liver disease

Information

Project Team

Organisations

Outputs and Outcomes

Publications

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression

Milton Boaheng AntwiSander LefereDorien ClarisseLisa KoorneefAnneleen HeldensLouis OnghenaKylian DecroixDaria FijalkowskaJonathan ThommisMadeleine HellemansAnne HoorensAnja GeertsLindsey DevisscherKarolien De Bosscher et al.

A1 Journal Article in METABOLISM-CLINICAL AND EXPERIMENTAL

2025

The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature

Anneleen HeldensChristophe CasteleynLouis OnghenaMilton Boaheng AntwiSara NeytBenedicte DescampsChristian VanhoveXavier VerhelstSarah RaevensHans Van VlierbergheLindsey DevisscherRuth De BruyneJean-Louis JunienGuillaume WettsteinAnja GeertsSander Lefere et al.

A1 Journal Article in BIOMEDICINE & PHARMACOTHERAPY

2025

Unlocking therapeutic potential : exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease

Milton Boaheng AntwiAriann JenningsSander LefereDorien ClarisseAnja GeertsLindsey DevisscherKarolien De Bosscher

A2 Journal Article in NPJ METABOLIC HEALTH AND DISEASE

2024